Genomics

EQS-News: 3M FY 23/24:  BRAIN Biotech looks optimistic to stay on the growth path for fiscal year 2023/24

Retrieved on: 
Wednesday, March 13, 2024

Adriaan Moelker, CEO BRAIN Biotech AG, states: “Our BioScience segment made a very strong start to the business year.

Key Points: 
  • Adriaan Moelker, CEO BRAIN Biotech AG, states: “Our BioScience segment made a very strong start to the business year.
  • The BRAIN Biotech Holding segment mainly includes personnel expenses and other expenses for Group administration, further development of the BRAIN Biotech Group, stock exchange listing and M&A activities.
  • CFO at BRAIN Biotech AG, Michael Schneiders, takes an optimistic view on the financial year 2023/24: “We aim to continue our organic growth path from the last two years.
  • The BRAIN Biotech Group now targets a revenue range of € 58 million to € 62 million for the new financial year.

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

Retrieved on: 
Monday, March 11, 2024

BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported positive proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics.

Key Points: 
  • BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported positive proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics.
  • Akribion Genomics, a German-based biotechnology start-up, is focused on a CRISPR-derived molecular complex for cancer treatment.
  • TransCode and Akribion are collaborating to develop a technology that combines Akribion’s cell-killing G-dase E, a Class 2 CRISPR nuclease, with TransCode's TTX nucleic acid delivery platform.
  • These studies also indicate that TTX-G-dase E ribonucleoprotein complexes could be taken up by cancer cells, inducing cancer cell death.

Gattaca Genomics Appoints Dr. Tyl Taylor as New Director of Genetics Services

Retrieved on: 
Thursday, March 7, 2024

Florida, March 06, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics, a leading name in genetic services, appoints Dr. Tyl Taylor as its new Director of Genetics Services.

Key Points: 
  • Florida, March 06, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics, a leading name in genetic services, appoints Dr. Tyl Taylor as its new Director of Genetics Services.
  • Dr. Taylor brings a wealth of experience and expertise in the field, making him a valuable addition to the Gattaca team.
  • In his role as the Director of Genetics Services at Gattaca, Dr. Taylor is poised to lead the team towards new heights in genetic research and reproductive technologies.
  • We are confident that under his guidance, Gattaca will continue to drive advancements in genetic services," said Michael Carbonara, CEO of Gattaca Genetics.

Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024

Retrieved on: 
Tuesday, March 5, 2024

Total revenue for the fourth quarter of 2023 was $10.7 million, an increase of 30% compared to the fourth quarter of 2022.

Key Points: 
  • Total revenue for the fourth quarter of 2023 was $10.7 million, an increase of 30% compared to the fourth quarter of 2022.
  • GAAP gross margin for the fourth quarter of 2023 was 23%, which was slightly higher than the 22% GAAP gross margin reported for the fourth quarter of 2022.
  • Fourth quarter 2023 GAAP operating expense was $27.4 million, compared to $39.3 million in the fourth quarter of 2022.
  • Fourth quarter 2023 non-GAAP operating expense was $27.3 million, compared to $30.6 million in the fourth quarter of 2022.

SOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, March 5, 2024

BOSTON and ROLLE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • BOSTON and ROLLE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2023.
  • SOPHiA GENETICS will host a conference call and live webcast to discuss the fourth quarter and full year 2023 results, and financial guidance for the full year 2024 on Tuesday, March 5, 2024, at 8:00 a.m. (08:00) Eastern Time / 2:00 p.m. (14:00) Central European Time.
  • Additionally, an audio replay of the conference call will be available on the SOPHiA GENETICS website after its completion.
  • These non-IFRS measures are key measures used by SOPHiA GENETICS management and board of directors to evaluate its operating performance and generate future operating plans.

Sandoz announces nominations to the Board of Directors and leadership change

Retrieved on: 
Tuesday, March 5, 2024

Gilbert Ghostine, Sandoz Chairman, said: "Our company evolves, and so does our leadership team.

Key Points: 
  • Gilbert Ghostine, Sandoz Chairman, said: "Our company evolves, and so does our leadership team.
  • I am pleased we can propose exceptional people in science and in business for election to the Board of Directors this year.
  • The new Board talent maintains the complementarity of expertise and experience in the areas relevant to Sandoz.
  • The following persons are recommended for election to the Board of Directors at the Annual General Meeting on April 30, 2024:

CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency

Retrieved on: 
Thursday, February 29, 2024

The study revealed that complete pre-TCRα deficiency is rare in humans and less severe than anticipated.

Key Points: 
  • The study revealed that complete pre-TCRα deficiency is rare in humans and less severe than anticipated.
  • Prof. Peter Bauer, Chief Medical and Genomic Officer at CENTOGENE, said, "This research advances our understanding of pre-TCRα deficiency significantly.
  • In analyzing genomic and phenomic data, CENTOGENE researchers helped establish the association between partial pre-TCRα deficiency and autoimmunity, with a higher prevalence than initially expected.
  • Christian Beetz, Senior Director Genomic Innovation at CENTOGENE, added, “Until now, the impact of pre-TCRα deficiency has been largely unknown.

Bionano to Present at TD Cowen’s 44th Annual Health Care Conference

Retrieved on: 
Thursday, February 29, 2024

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at TD Cowen’s 44th Annual Health Care Conference on March 6, 2024.

Key Points: 

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at TD Cowen’s 44th Annual Health Care Conference on March 6, 2024.

New RSC Event: "Water is Life: Sustainability of Our Oceans"

Retrieved on: 
Wednesday, February 28, 2024

Toronto, Ontario, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The Royal Society of Canada (RSC) and Massey College are thrilled to present the third installment of the RSC Dialogues @ Massey series, Water is Life: Sustainability of Our Oceans.

Key Points: 
  • Toronto, Ontario, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The Royal Society of Canada (RSC) and Massey College are thrilled to present the third installment of the RSC Dialogues @ Massey series, Water is Life: Sustainability of Our Oceans.
  • At this event, speakers will explore the topic of water sustainability with a focus on habitats, climate change, and Indigenous sovereignty.
  • Dr. Cheung is recognized internationally for his research on the interconnections among climate change, food security and biodiversity conservation in marine environments.
  • As a marine ecologist and fisheries scientist, Dr. Cheung's work addresses policy-relevant research questions through a transdisciplinary lens that encompasses oceanography, ecology, economics, and social sciences.

AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors

Retrieved on: 
Wednesday, February 28, 2024

Dr. Pfost noted, “AxoSim embodies the entrepreneur’s sweet spot--when market need, technological innovation, timing and team all align. The growing prevalence of neurological diseases places enormous burdens on patients, their families and society. Yet despite billions in investment, neurology R&D continues to disappoint. AxoSim’s transformational approach addresses a key contributor to these failures—the lack of relevant disease models—by providing functional human data from its microphysiological system (MPS) organoid technologies early in the process. AxoSim aims to become an industry leader in helping to deliver urgently needed new drugs and I welcome the opportunity to contribute to its success.”

Key Points: 
  • Dr. Pfost and Dr. Weiner have decades of experience in building successful biotechnology companies spanning therapeutics, diagnostics and life science tools and technologies.
  • “Our recent acquisition of a third platform technology positions AxoSim for growth, and we are fortunate to have these two talented industry veterans assuming key leadership roles,” said Lowry Curley, PhD, co-founder and Chief Executive Officer of AxoSim.
  • “Dale and Dave bring successful track records in building life sciences businesses, with broad and complementary skill sets.
  • Dale’s work in life science tools and venture finance is highly relevant, as is Dave’s expertise in leading neurological drug discovery and clinical development.